Antonio García‐Merino

Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension

Raju Kapoor, Pei‐Ran Ho, Nolan Campbell et al. · The Lancet Neurology · 2018 · 337 citations · Full text

Life Sciences, Neurology, Pharmacotherapy +14

Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring

Ludwig Kappos, David O. Bates, Gilles Edan et al. · The Lancet Neurology · 2011 · 266 citations · Full text

Life Sciences, Neurology, Pharmacotherapy +10

Safety and efficacy of opicinumab in patients with relapsing multiple sclerosis (SYNERGY): a randomised, placebo-controlled, phase 2 trial

Diego Cadavid, Michelle Mellion, Raymond Hupperts et al. · The Lancet Neurology · 2019 · 185 citations

Life Sciences, Immunology, Neurology +11

Neurofilament light chain and oligoclonal bands are prognostic biomarkers in radiologically isolated syndrome

Clara Matute‐Blanch, Luisa María Villar, José C. Álvarez‐Cermeño et al. · Brain · 2018 · 161 citations

Life Sciences, Neurology, Neuroscience +16

Decreased endocannabinoid levels in the brain and beneficial effects of agents activating cannabinoid and/or vanilloid receptors in a rat model of multiple sclerosis

Ana Cabranes, Kateřina Venderová, Eva de Lago et al. · Neurobiology of Disease · 2005 · 133 citations · Full text

Life Sciences, Neuroscience, Pharmacology +17